Posted on by Lawrence Tabak, D.D.S., Ph.D.
On May 11, I was pleased to appear before the U.S. House of Representatives Subcommittee on Labor, Health and Human Services, Education, and Related Agencies to discuss NIH’s budget request for Fiscal Year 2023. Joining me (left to right) were leaders of several NIH institutes: Nora Volkow, National Institute on Drug Abuse; Tony Fauci, National Institute of Allergy and Infectious Diseases; Diana Bianchi, Eunice Kennedy Shriver National Institute of Child Health and Human Development; Doug Lowy, National Cancer Institute; and Gary Gibbons, National Heart, Lung, and Blood Institute.
Posted on by Dr. Sally Rockey and Dr. Francis Collins
“It was the best of times, it was the worst of times.” Until recently, we’d never have dreamed of mentioning the famous opening line of Charles Dickens’ Tale of Two Cities in the context of U.S. biomedical research. But now those words ring all too true.
The “best of times” reflects the amazing technological advances and unprecedented scientific opportunities that exist right now. We’ve never had a better chance to make rapid progress in preventing, diagnosing, and curing human disease. But the “worst of times” is the other reality: NIH’s ability to support vital research at more than 2,500 universities and organizations across the nation is reeling from a decline in funding that threatens our health, our economy, and our standing as the world leader in biomedical innovation.